Thank you very much indeed for such an informative lecture. I started taking Mavacamten, here in the United Kingdom, only two weeks ago (we are behind the US in distributing this First in Class medication). So it is early days but I remain cautiously optimistic. Whilst I have tried to keep up with the trial data for these CMI medications, I found your discussion of the clinical management very helpful. The possibility of long-term remodelling remains tantalising, but for now I need to be cautiously optimistic about receiving improvements in my symptoms and NYHA status over the coming months.
